Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

@article{Lu2016InhibitionOT,
  title={Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.},
  author={Ailing Lu and Manuel Antonio Pallero and Weiqi Lei and Huixian Hong and Yang Yang and Mark J. Suto and Joanne E Murphy-Ullrich},
  journal={The American journal of pathology},
  year={2016},
  volume={186 3},
  pages={
          678-90
        }
}
Transforming growth factor (TGF)-β supports multiple myeloma progression and associated osteolytic bone disease. Conversion of latent TGF-β to its biologically active form is a major regulatory node controlling its activity. Thrombospondin1 (TSP1) binds and activates TGF-β. TSP1 is increased in myeloma, and TSP1-TGF-β activation inhibits osteoblast differentiation. We hypothesized that TSP1 regulates TGF-β activity in myeloma and that antagonism of the TSP1-TGF-β axis inhibits myeloma… CONTINUE READING
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND & RESULTS